Digging deep into "dirty" drugs-modulation of the methylation machinery

Drug Metabolism Reviews

Volumn 47, Issue 2, 2015, Pages 252-279

  Pleyer, Lisa ^a   Greil, Richard ^a  

^a PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

Acute myeloid leukemia; Azacitidine; Decitabine; DNA methylation; Epigenetics; Hypomethylating agents; Myelodysplastic syndrome; Transcriptional regulation

Indexed keywords

AZACITIDINE; DECITABINE; MESSENGER RNA; RIBONUCLEOTIDE REDUCTASE; ANTINEOPLASTIC ANTIMETABOLITE;

ACUTE MYELOBLASTIC LEUKEMIA; CLINICAL TRIAL (TOPIC); DNA METHYLATION; DRUG MECHANISM; EPIGENETICS; GENE CONTROL; GENE SILENCING; HISTONE MODIFICATION; MYELODYSPLASTIC SYNDROME; PROTEIN METABOLISM; REVIEW; TRANSCRIPTION REGULATION; ANALOGS AND DERIVATIVES; ANIMAL; DRUG EFFECTS; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; GENETICS; HISTONE CODE; HUMAN; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; HISTONE CODE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MYELODYSPLASTIC SYNDROMES; TRANSCRIPTION, GENETIC;

EID: 84929149776     PISSN: 03602532     EISSN: 10979883     Source Type: Journal    
DOI: 10.3109/03602532.2014.995379     Document Type: Review

References (362)

1. Abdel-Wahab O, Adli M, LaFave LM, et al. (2012). ASXL1 mutations promote myeloid transformation through loss of PRC2-mediated gene repression. Cancer Cell 22:180-193.
2. Abdel-Wahab O, Gao J, Adli M, et al. (2013). Deletion of Asxl1 results in myelodysplasia and severe developmental defects in vivo. J Exp Med 210:2641-2659.
3. Abdel-Wahab O, Levine RL. (2013). Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood 121:3563-3572.
4. Abdel-Wahab O, Mullally A, Hedvat C, et al. (2009). Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood 114:144-147.
5. Abdel-Wahab O, Pardanani A, Patel J, et al. (2011). Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms. Leukemia 25:1200-1202.
6. Abusnina A, Keravis T, Yougbare I, et al. (2011). Anti-proliferative effect of curcumin on melanoma cells is mediated by PDE1A inhibition that regulates the epigenetic integrator UHRF1. Mol Nutr Food Res 55:1677-1689.
7. Aimiuwu J, Wang H, Chen P, et al. (2012). RNA-dependent inhibition of ribonucleotide reductase is a major pathway for 5-Azacytidine activity in acute myeloid leukemia. Blood 119:5229-5238.
8. Alharbi RA, Pettengell R, Pandha HS, Morgan R. (2013). The role of HOX genes in normal hematopoiesis and acute leukemia. Leukemia 27:1000-1008.
9. Amiel J, de PL, Henrion-Caude A. (2012). miRNA, development and disease. Adv Genet 80:1-36.
10. Anand R, Marmorstein R. (2007). Structure and mechanism of lysinespecific demethylase enzymes. J Biol Chem 282:35425-35429.
11. Aoyama S, Nakano H, Danbara M, et al. (2012). The differentiating and apoptotic effects of 2-Aza-50-deoxycytidine are dependent on the PU.1 expression level in PU.1-Transgenic K562 cells. Biochem Biophys Res Commun 420:775-781.
12. Argiropoulos B, Humphries RK. (2007). Hox genes in hematopoiesis and leukemogenesis. Oncogene 26:6766-6776.
13. Bartholdy B, Christopeit M, Will B, et al. (2014). HSC commitmentassociated epigenetic signature is prognostic in acute myeloid leukemia. J Clin Invest 124:1158-1167.
14. Basecke J, Whelan JT, Griesinger F, Bertrand FE. (2006). The MLL partial tandem duplication in acute myeloid leukaemia. Br J Haematol 135:438-449.
15. Basova P, Pospisil V, Savvulidi F, et al. (2013). Aggressive acute myeloid leukemia in PU.1/p53 double-mutant mice. Oncogene 33: 4735-4745.
16. Baubec T, Ivanek R, Lienert F, Schubeler D. (2013). Methylationdependent and-independent genomic targeting principles of the MBD protein family. Cell 153:480-492.
17. Bejar R, Stevenson K, Abdel-Wahab O, et al. (2011). Clinical effect of point mutations in myelodysplastic syndromes. N Engl J Med 364: 2496-2506.
18. Beumer JH, Parise RA, Newman EM, et al. (2008). Concentrations of the DNA methyltransferase inhibitor 5-fluoro-20-deoxycytidine (FdCyd) and its cytotoxic metabolites in plasma of patients treated with FdCyd and tetrahydrouridine (THU). Cancer Chemother Pharmacol 62: 363-368.
19. Bird A. (2007). Perceptions of epigenetics. Nature 447:396-398.
20. Bonadies N, Pabst T, Mueller BU. (2010). Heterozygous deletion of the PU.1 locus in human AML. Blood 115:331-334.
21. Bostick M, Kim JK, Esteve PO, et al. (2007). UHRF1 plays a role in maintaining DNA methylation in mammalian cells. Science 317: 1760-1764.
22. Boultwood J, Perry J, Pellagatti A, et al. (2010). Frequent mutation of the polycomb-Associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia. Leukemia 24:1062-1065.
23. Bourc'his D, Xu GL, Lin CS, et al. (2001). Dnmt3L and the establishment of maternal genomic imprints. Science 294:2536-2539.
24. Bracken AP, Pasini D, Capra M, et al. (2003). EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22:5323-5335.
25. Braun T, Itzykson R, Renneville A, et al. (2011). Molecular predictors of response to decitabine in advanced chronic myelomonocytic leukemia: A phase 2 trial. Blood 118:3824-3831.
26. Bronner C, Achour M, Arima Y, et al. (2007). The UHRF family: Oncogenes that are drugable targets for cancer therapy in the near future?. Pharmacol Ther 115:419-434.
27. Bronner C, Krifa M, Mousli M. (2013). Increasing role of UHRF1 in the reading and inheritance of the epigenetic code as well as in tumorogenesis. Biochem Pharmacol 86:1643-1649.
28. Camos M, Esteve J, Jares P, et al. (2006). Gene expression profiling of acute myeloid leukemia with translocation t(8;16)(p11;p13) and MYST3-CREBBP rearrangement reveals a distinctive signature with a specific pattern of HOX gene expression. Cancer Res 66: 6947-6954.
29. Cedar H, Bergman Y. (2009). Linking DNA methylation and histone modification: Patterns and paradigms. Nat Rev Genet 10:295-304.
30. Cervantes F. (2014). How I treat myelofibrosis. Blood 124:2635-2642.
31. Chabot GG, Rivard GE, Momparler RL. (1983). Plasma and cerebrospinal fluid pharmacokinetics of 5-Aza-20-deoxycytidine in rabbits and dogs. Cancer Res 43:592-597.
32. Chaturvedi A, Araujo Cruz MM, Jyotsana N, et al. (2013). Mutant IDH1 promotes leukemogenesis in vivo and can be specifically targeted in human AML. Blood 122:2877-2887.
33. Chen C, Liu Y, Rappaport AR, et al. (2014). MLL3 is a haploinsufficient 7q tumor suppressor in acute myeloid leukemia. Cancer Cell 25: 652-665.
34. Cheng JX, Anastasi J, Watanabe K, et al. (2013). Genome-wide profiling reveals epigenetic inactivation of the PU.1 pathway by histone H3 lysine 27 trimethylation in cytogenetically normal myelodysplastic syndrome. Leukemia 27:1291-1300.
35. Choi SH, Byun HM, Kwan JM, et al. (2007). Hydroxycarbamide in combination with azacitidine or decitabine is antagonistic on DNA methylation inhibition. Br J Haematol 138:616-623.
36. Chowdhury R, Yeoh KK, Tian YM, et al. (2011). The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO Rep 12:463-469.
37. Christiansen DH, Andersen MK, Pedersen-Bjergaard J. (2003). Methylation of p15INK4B is common, is associated with deletion of genes on chromosome arm 7q and predicts a poor prognosis in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia 17:1813-1819.
38. Christman JK. (2002). 5-Azacytidine and 5-Aza-20-deoxycytidine as inhibitors of DNA methylation: Mechanistic studies and their implications for cancer therapy. Oncogene 21:5483-5495.
39. Chung SS, Park CY. (2014). MicroRNA dysregulation in the myelodysplastic syndromes. Microrna 2:174-186.
40. Cihak A, Weiss JW, Pitot HC. (1974). Characterization of polyribosomes and maturation of ribosomal RNA in hepatoma cells treated with 5-Azacytidine. Cancer Res 34:3003-3009.
41. Claus R, Pfeifer D, Almstedt M, et al. (2013). Decitabine induces very early in vivo DNA methylation changes in blasts from patients with acute myeloid leukemia. Leuk Res 37:190-196.
42. Cohen S, Megherbi M, Jordheim LP, et al. (2009). Simultaneous analysis of eight nucleoside triphosphates in cell lines by liquid chromatography coupled with tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 877:3831-3840.
43. Copeland RA, Solomon ME, Richon VM. (2009). Protein methyltransferases as a target class for drug discovery. Nat Rev Drug Discov 8: 724-732.
44. Copur O, Muller J. (2013). The histone H3-K27 demethylase Utx regulates HOX gene expression in Drosophila in a temporally restricted manner. Development 140:3478-3485.
45. Costello JF, Fruhwald MC, Smiraglia DJ, et al. (2000). Aberrant CpGisland methylation has non-random and tumour-Type-specific patterns. Nat Genet 24:132-138.
46. Creusot F, Acs G, Christman JK. (1982). Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-Azacytidine and 5-Aza-20-deoxycytidine. J Biol Chem 257:2041-2048.
47. Curik N, Burda P, Vargova K, et al. (2012). 5-Azacitidine in aggressive myelodysplastic syndromes regulates chromatin structure at PU.1 gene and cell differentiation capacity. Leukemia 26:1804-1811.
48. Curt GA, Kelley JA, Fine RL, et al. (1985). A phase I and pharmacokinetic study of dihydro-5-Azacytidine (NSC 264880). Cancer Res 45:3359-3363.
49. Daigle SR, Olhava EJ, Therkelsen CA, et al. (2011). Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 20:53-65.
50. Daigle SR, Olhava EJ, Therkelsen CA, et al. (2013). Potent inhibition of DOT1L as treatment of MLL-fusion leukemia. Blood 122: 1017-1025.
51. Dallosso AR, Oster B, Greenhough A, et al. (2012). Long-range epigenetic silencing of chromosome 5q31 protocadherins is involved in early and late stages of colorectal tumorigenesis through modulation of oncogenic pathways. Oncogene 31:4409-4419.
52. Dalmasso MC, Onyango DO, Naguleswaran A, et al. (2009). Toxoplasma H2A variants reveal novel insights into nucleosome composition and functions for this histone family. J Mol Biol 392: 33-47.
53. Damaraju VL, Mowles D, Yao S, et al. (2012). Role of human nucleoside transporters in the uptake and cytotoxicity of azacitidine and decitabine. Nucleosides Nucleotides Nucleic Acids 31:236-255.
54. Dang L, White DW, Gross S, et al. (2009). Cancer-Associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462:739-744.
55. Daser A, Rabbitts TH. (2005). The versatile mixed lineage leukaemia gene MLL and its many associations in leukaemogenesis. Semin Cancer Biol 15:175-188.
56. Daskalakis M, Nguyen TT, Nguyen C, et al. (2002). Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-20-deoxycytidine (decitabine) treatment. Blood 100:2957-2964.
57. Datta J, Ghoshal K, Motiwala T, Jacob ST. (2012). Novel insights into the molecular mechanism of action of DNA hypomethylating agents: Role of protein kinase C delta in decitabine-induced degradation of DNA methyltransferase 1. Genes Cancer 3:71-81.
58. Davis MI, Gross S, Shen M, et al. (2014). Biochemical, cellular and biophysical characterization of a potent inhibitor of mutant isocitrate dehydrogenase IDH1. J Biol Chem 289:13717-13725.
59. Dawson MA, Gudgin EJ, Horton SJ, et al. (2014). Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia 28:311-320.
60. de la Cruz X, Lois S, Sanchez-Molina S, Martinez-Balbas MA. (2005). Do protein motifs read the histone code?. Bioessays 27: 164-175.
61. de Lavallade H, Khoder A, Hart M, et al. (2013). Tyrosine kinase inhibitors impair B-cell immune responses in CML through off-Target inhibition of kinases important for cell signaling. Blood 122:227-238.
62. Deeg HJ, Gotlib J, Beckham C, et al. (2002). Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: A pilot study. Leukemia 16:162-164.
63. Delmore JE, Issa GC, Lemieux ME, et al. (2011). BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146:904-917.
64. Derissen EJ, Hillebrand MJ, Rosing H, et al. (2014). Quantitative determination of azacitidine triphosphate in peripheral blood mononuclear cells using liquid chromatography coupled with highresolution mass spectrometry. J Pharm Biomed Anal 90:7-14.
65. Deshpande AJ, Chen L, Fazio M, et al. (2013). Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l. Blood 121:2533-2541.
66. Dickstein J, Senyuk V, Premanand K, et al. (2010). Methylation and silencing of miRNA-124 by EVI1 and self-renewal exhaustion of hematopoietic stem cells in murine myelodysplastic syndrome. Proc Natl Acad Sci USA 107:9783-9788.
67. Dobbelstein M, Moll U. (2014). Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov 13:179-196.
68. Dolnik A, Engelmann JC, Scharfenberger-Schmeer M, et al. (2012). Commonly altered genomic regions in acute myeloid leukemia are enriched for somatic mutations involved in chromatin remodeling and splicing. Blood 120:e83-e92.
69. Doyle B, Fudenberg G, Imakaev M, Mirny LA. (2014). Chromatin loops as allosteric modulators of enhancer-promoter interactions. PLoS Comput Biol 10:e1003867.
70. Duhoux FP, Ameye G, Montano-Almendras CP, et al. (2012). PRDM16 (1p36) translocations define a distinct entity of myeloid malignancies with poor prognosis but may also occur in lymphoid malignancies. Br J Haematol 156:76-88.
71. Easwaran HP, Schermelleh L, Leonhardt H, Cardoso MC. (2004). Replication-independent chromatin loading of Dnmt1 during G2 and M phases. EMBO Rep 5:1181-1186.
72. Eklund E. (2011). The role of Hox proteins in leukemogenesis: Insights into key regulatory events in hematopoiesis. Crit Rev Oncog 16:65-76.
73. Eliopoulos N, Cournoyer D, Momparler RL. (1998). Drug resistance to 5-Aza-20-deoxycytidine, 20, 20-difluorodeoxycytidine, and cytosine arabinoside conferred by retroviral-mediated transfer of human cytidine deaminase cDNA into murine cells. Cancer Chemother Pharmacol 42:373-378.
74. El-Sharkawi D, Ali A, Evans CM, et al. (2014). ASXL1 mutations are infrequent in young patients with primary acute myeloid leukemia and their detection has a limited role in therapeutic risk stratification. Leuk Lymphoma 55:1326-1331.
75. Erdogan B, Facey C, Qualtieri J, et al. (2011). Diagnostic microRNAs in myelodysplastic syndrome. Exp Hematol 39:915-926.
76. Erikci AA, Ozturk A, Karagoz B, et al. (2008). Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia. Hematology 13:289-292.
77. Ersvaer E, Hampson P, Hatfield K, et al. (2007). T cells remaining after intensive chemotherapy for acute myelogenous leukemia show a broad cytokine release profile including high levels of interferon-gamma that can be further increased by a novel protein kinase C agonist PEP005. Cancer Immunol Immunother 56:913-925.
78. Ersvaer E, Kittang AO, Hampson P, et al. (2010). The protein kinase C agonist PEP005 (ingenol 3-Angelate) in the treatment of human cancer: A balance between efficacy and toxicity. Toxins (Basel) 2: 174-194.
79. Esteller M. (2007). Epigenetic gene silencing in cancer: The DNA hypermethylome. Hum Mol Genet 16 Spec No 1:R50-R59.
80. Falkenberg KJ, Johnstone RW. (2014). Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders. Nat Rev Drug Discov 13:673-691.
81. Fandy TE, Herman JG, Kerns P, et al. (2009). Early epigenetic changes and DNA damage do not predict clinical response in an overlapping schedule of 5-Azacytidine and entinostat in patients with myeloid malignancies. Blood 114:2764-2773.
82. Fathi AT, Abdel-Wahab O. (2012). Mutations in epigenetic modifiers in myeloid malignancies and the prospect of novel epigenetic-Targeted therapy. Adv Hematol 2012: Article ID 469592, 12 pages, doi: 10.1155/2012/469592.
83. Feinberg AP, Tycko B. (2004). The history of cancer epigenetics. Nat Rev Cancer 4:143-153.
84. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. (2009). Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: A randomised, open-label, phase III study. Lancet Oncol 10:223-232.
85. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. (2010). Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 28:562-569.
86. Ferraris D, Duvall B, Delahanty G, et al. (2014). Design, synthesis, and pharmacological evaluation of fluorinated tetrahydrouridine derivatives as inhibitors of cytidine deaminase. J Med Chem 57: 2582-2588.
87. Ferreira BV, Harrison C. (2014). How many JAK inhibitors in myelofibrosis?. Best Pract Res Clin Haematol 27:187-195.
88. Figueroa ME, Lugthart S, Li Y, et al. (2010). DNA methylation signatures identify biologically distinct subtypes in acute myeloid leukemia. Cancer Cell 17:13-27.
89. Figueroa ME, Skrabanek L, Li Y, et al. (2009). MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation. Blood 114:3448-3458.
90. Filippakopoulos P, Picaud S, Mangos M, et al. (2012). Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149:214-231.
91. Fiskus W, Sharma S, Qi J, et al. (2014). BET protein antagonist JQ1 is synergistically lethal with FLT3 tyrosine kinase inhibitor (TKI) and overcomes resistance to FLT3-TKI in AML cells expressing FLT-ITD. Mol Cancer Ther 13:2315-2327.
92. Fiskus W, Sharma S, Qi J, et al. (2014). Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells. Mol Cancer Ther 13: 1142-1154.
93. Fiskus W, Sharma S, Shah B, et al. (2014). Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells. Leukemia 28:2155-2164.
94. Fiskus W, Wang Y, Sreekumar A, et al. (2009). Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114:2733-2743.
95. Flemming A. (2012). Deal watch: Epizyme-Celgene deal signals interest in new class of epigenetic drugs. Nat Rev Drug Discov 11:508.
96. Flotho C, Claus R, Batz C, et al. (2009). The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 23:1019-1028.
97. Fog CK, Galli GG, Lund AH. (2012). PRDM proteins: Important players in differentiation and disease. Bioessays 34:50-60.
98. Forn M, Munoz M, Tauriello DV, et al. (2013). Long range epigenetic silencing is a trans-species mechanism that results in cancer specific deregulation by overriding the chromatin domains of normal cells. Mol Oncol 7:1129-1141.
99. Fu Y, Sinha M, Peterson CL, Weng Z. (2008). The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet 4:e1000138.
100. Fuks F, Hurd PJ, Wolf D, et al. (2003). The methyl-CpG-binding protein MeCP2 links DNA methylation to histone methylation. J Biol Chem 278:4035-4040.
101. Galmarini CM, Graham K, Thomas X, et al. (2001). Expression of high Km 50-nucleotidase in leukemic blasts is an independent prognostic factor in adults with acute myeloid leukemia. Blood 98:1922-1926.
102. Galmarini CM, Thomas X, Graham K, et al. (2003). Deoxycytidine kinase and cN-II nucleotidase expression in blast cells predict survival in acute myeloid leukaemia patients treated with cytarabine. Br J Haematol 122:53-60.
103. Ganan-Gomez I, Wei Y, Yang H, et al. (2014). Overexpression of miR-125a in myelodysplastic syndrome CD34+ cells modulates NFkappaB activation and enhances erythroid differentiation arrest. PLoS One 9:e93404.
104. Garcia-Manero G, Gore SD, Cogle C, et al. (2011). Phase I study of oral azacitidine in myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. J Clin Oncol 29:2521-2527.
105. Garcia-Manero G. (2012). Can we improve outcomes in patients with acute myelogenous leukemia?. Incorporating HDAC inhibitors into front-line therapy. Best Pract Res Clin Haematol 25:427-435.
106. Garzon R, Liu S, Fabbri M, et al. (2009). MicroRNA-29b induces global DNA hypomethylation and tumor suppressor gene reexpression in acute myeloid leukemia by targeting directly DNMT3A and 3B and indirectly DNMT1. Blood 113:6411-6418.
107. Ghoshal K, Datta J, Majumder S, et al. (2002). Inhibitors of histone deacetylase and DNA methyltransferase synergistically activate the methylated metallothionein I promoter by activating the transcription factor MTF-1 and forming an open chromatin structure. Mol Cell Biol 22:8302-8319.
108. Ghoshal K, Datta J, Majumder S, et al. (2005). 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-Adjacent homology domain, and nuclear localization signal. Mol Cell Biol 25: 4727-4741.
109. Gius D, Cui H, Bradbury CM, et al. (2004). Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. Cancer Cell 6: 361-371.
110. Glover AB, Leyland-Jones B. (1987). Biochemistry of azacitidine: A review. Cancer Treat Rep 71:959-964.
111. Goldberg AD, Allis CD, Bernstein E. (2007). Epigenetics: A landscape takes shape. Cell 128:635-638.
112. Goll MG, Kirpekar F, Maggert KA, et al. (2006). Methylation of tRNAAsp by the DNA methyltransferase homolog Dnmt2. Science 311:395-398.
113. Gong JN, Yu J, Lin HS, et al. (2014). The role, mechanism and potentially therapeutic application of microRNA-29 family in acute myeloid leukemia. Cell Death Differ 21:100-112.
114. Gowher H, Loutchanwoot P, Vorobjeva O, et al. (2006). Mutational analysis of the catalytic domain of the murine Dnmt3a DNA-(cytosine C5)-methyltransferase. J Mol Biol 357:928-941.
115. Green CL, Evans CM, Hills RK, et al. (2010). The prognostic significance of IDH1 mutations in younger adult patients with acute myeloid leukemia is dependent on FLT3/ITD status. Blood 116: 2779-2782.
116. Green CL, Evans CM, Zhao L, et al. (2011). The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. Blood 118:409-412.
117. Gronbaek K, Muller-Tidow C, Perini G, et al. (2012). A critical appraisal of tools available for monitoring epigenetic changes in clinical samples from patients with myeloid malignancies. Haematologica 97: 1380-1388.
118. Grossmann V, Kohlmann A, Eder C, et al. (2011). Molecular profiling of chronic myelomonocytic leukemia reveals diverse mutations in480% of patients with TET2 and EZH2 being of high prognostic relevance. Leukemia 25:877-879.
119. Guan D, Factor D, Liu Y, et al. (2013). The epigenetic regulator UHRF1 promotes ubiquitination-mediated degradation of the tumorsuppressor protein promyelocytic leukemia protein. Oncogene 32: 3819-3828.
120. Guo D, Myrdal PB, Karlage KL, et al. (2010). Stability of 5-fluoro-20-deoxycytidine and tetrahydrouridine in combination. AAPS PharmSciTech 11:247-252.
121. Gurion R, Vidal L, Gafter-Gvili A, et al. (2010). 5-Azacitidine prolongs overall survival in patients with myelodysplastic syndrome-A systematic review and meta-Analysis. Haematologica 95:303-310.
122. Hampson P, Chahal H, Khanim F, et al. (2005). PEP005, a selective small-molecule activator of protein kinase C, has potent antileukemic activity mediated via the delta isoform of PKC. Blood 106: 1362-1368.
123. Harmston N, Lenhard B. (2013). Chromatin and epigenetic features of long-range gene regulation. Nucleic Acids Res 41:7185-7199.
124. Herman JG, Baylin SB. (2003). Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med 349:2042-2054.
125. Herrera-Merchan A, Arranz L, Ligos JM, et al. (2012). Ectopic expression of the histone methyltransferase Ezh2 in haematopoietic stem cells causes myeloproliferative disease. Nat Commun 3:623. doi: 10.1038/ncomms1623.
126. Hohenauer T, Moore AW. (2012). The Prdm family: Expanding roles in stem cells and development. Development 139:2267-2282.
127. Hollenbach PW, Nguyen AN, Brady H, et al. (2010). A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS One 5:e9001.
128. Honjo T, Muramatsu M, Fagarasan S. (2004). AID: How does it aid antibody diversity?. Immunity 20:659-668.
129. Hopfer O, Komor M, Koehler IS, et al. (2009). Aberrant promotor methylation in MDS hematopoietic cells during in vitro lineage specific differentiation is differently associated with DNMT isoforms. Leuk Res 33:434-442.
130. Hubeek I, Stam RW, Peters GJ, et al. (2005). The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia. Br J Cancer 93:1388-1394.
131. Hwang CK, Kim CS, Choi HS, et al. (2004). Transcriptional regulation of mouse mu opioid receptor gene by PU.1. J Biol Chem 279: 19764-19774.
132. Ikegami K, Ohgane J, Tanaka S, et al. (2009). Interplay between DNA methylation, histone modification and chromatin remodeling in stem cells and during development. Int J Dev Biol 53: 203-214.
133. Inoue D, Kitaura J, Togami K, et al. (2013). Myelodysplastic syndromes are induced by histone methylation-Altering ASXL1 mutations. J Clin Invest 123:4627-4640.
134. Issa JP. (2010). Epigenetic changes in the myelodysplastic syndrome. Hematol Oncol Clin North Am 24:317-330.
135. Itzykson R, Fenaux P. (2014). Epigenetics of myelodysplastic syndromes. Leukemia 28:497-506.
136. Itzykson R, Kosmider O, Cluzeau T, et al. (2011). Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia 25: 1147-1152.
137. Itzykson R, Kosmider O, Renneville A, et al. (2013). Prognostic score including gene mutations in chronic myelomonocytic leukemia. J Clin Oncol 31:2428-2436.
138. Jaenisch R, Bird A. (2003). Epigenetic regulation of gene expression: How the genome integrates intrinsic and environmental signals. Nat Genet 33:245-254.
139. Jansen RS, Rosing H, Wijermans PW, et al. (2012). Decitabine triphosphate levels in peripheral blood mononuclear cells from patients receiving prolonged low-dose decitabine administration: A pilot study. Cancer Chemother Pharmacol 69:1457-1466.
140. Jeanblanc M, Mousli M, Hopfner R, et al. (2005). The retinoblastoma gene and its product are targeted by ICBP90: A key mechanism in the G1/S transition during the cell cycle. Oncogene 24:7337-7345.
141. Jiang Y, Dunbar A, Gondek LP, et al. (2009). Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 113: 1315-1325.
142. Jin C, Lu Y, Jelinek J, et al. (2014). TET1 is a maintenance DNA demethylase that prevents methylation spreading in differentiated cells. Nucleic Acids Res 42:6956-6971.
143. Jin SG, Jiang Y, Qiu R, et al. (2011). 5-Hydroxymethylcytosine is strongly depleted in human cancers but its levels do not correlate with IDH1 mutations. Cancer Res 71:7360-7365.
144. Johnstone RW. (2002). Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1:287-299.
145. Jones PA, Taylor SM, Wilson VL. (1983). Inhibition of DNA methylation by 5-Azacytidine. Recent Results Cancer Res 84:202-211.
146. Jones PA, Taylor SM. (1980). Cellular differentiation, cytidine analogs and DNA methylation. Cell 20:85-93.
147. Jongen-Lavrencic M, Sun SM, Dijkstra MK, et al. (2008). MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:5078-5085.
148. Kantarjian HM, Thomas XG, Dmoszynska A, et al. (2012). Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol 30:2670-2677.
149. Karahoca M, Momparler RL. (2013). Pharmacokinetic and pharmacodynamic analysis of 5-Aza-20-deoxycytidine (decitabine) in the design of its dose-schedule for cancer therapy. Clin Epigenetics 5:3. doi: 10.1186/1868-7083-5-3.
150. Karlic H, Herrmann H, Varga F, et al. (2014). The role of epigenetics in the regulation of apoptosis in myelodysplastic syndromes and acute myeloid leukemia. Crit Rev Oncol Hematol 90:1-16.
151. Karpinski P, Ramsey D, Grzebieniak Z, et al. (2008). The CpG island methylator phenotype correlates with long-range epigenetic silencing in colorectal cancer. Mol Cancer Res 6:585-591.
152. Kedei N, Lundberg DJ, Toth A, et al. (2004). Characterization of the interaction of ingenol 3-Angelate with protein kinase C. Cancer Res 64:3243-3255.
153. Khan H, Vale C, Bhagat T, Verma A. (2013). Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes. Semin Hematol 50:16-37.
154. Kihara-Negishi F, Yamamoto H, Suzuki M, et al. (2001). In vivo complex formation of PU.1 with HDAC1 associated with PU.1-mediated transcriptional repression. Oncogene 20:6039-6047.
155. Kim CH, Marquez VE, Mao DT, et al. (1986). Synthesis of pyrimidin-2-one nucleosides as acid-stable inhibitors of cytidine deaminase. J Med Chem 29:1374-1380.
156. Kim MK, Lee JL, Cho HS, et al. (2006). The hematologic response to anti-Apoptotic cytokine therapy: Results of pentoxifylline, ciprofloxacin, and dexamethasone treatment for patients with myelodysplastic syndrome. J Korean Med Sci 21:40-45.
157. Kinoshita K, Nonaka T. (2006). The dark side of activation-induced cytidine deaminase: Relationship with leukemia and beyond. Int J Hematol 83:201-207.
158. Klco JM, Spencer DH, Lamprecht TL, et al. (2013). Genomic impact of transient low-dose decitabine treatment on primary AML cells. Blood 121:1633-1643.
159. Klose RJ, Kallin EM, Zhang Y. (2006). JmjC-domain-containing proteins and histone demethylation. Nat Rev Genet 7:715-727.
160. Knutson SK, Wigle TJ, Warholic NM, et al. (2012). A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells. Nat Chem Biol 8:890-896.
161. Ko M, Huang Y, Jankowska AM, et al. (2010). Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2. Nature 468:839-843.
162. Kogure M, Takawa M, Saloura V, et al. (2013). The oncogenic polycomb histone methyltransferase EZH2 methylates lysine 120 on histone H2B and competes ubiquitination. Neoplasia 15: 1251-1261.
163. Koivunen J, Aaltonen V, Peltonen J. (2006). Protein kinase C (PKC) family in cancer progression. Cancer Lett 235:1-10.
164. Kon A, Shih LY, Minamino M, et al. (2013). Recurrent mutations in multiple components of the cohesin complex in myeloid neoplasms. Nat Genet 45:1232-1237.
165. Kosmider O, Gelsi-Boyer V, Cheok M, et al. (2009). TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 114:3285-3291.
166. Kosmider O, Gelsi-Boyer V, Ciudad M, et al. (2009). TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. Haematologica 94:1676-1681.
167. Kratzke RA, Wang X, Wong L, et al. (2008). Response to the methylation inhibitor dihydro-5-Azacytidine in mesothelioma is not associated with methylation of p16INK4a: Results of cancer and leukemia group B 159904. J Thorac Oncol 3:417-421.
168. Krivtsov AV, Feng Z, Lemieux ME, et al. (2008). H3K79 methylation profiles define murine and human MLL-AF4 leukemias. Cancer Cell 14:355-368.
169. Kroeger H, Jelinek J, Estecio MR, et al. (2008). Aberrant CpG island methylation in acute myeloid leukemia is accentuated at relapse. Blood 112:1366-1373.
170. Kumar A, List AF, Hozo I, et al. (2010). Decitabine versus 5-Azacitidine for the treatment of myelodysplastic syndrome: Adjusted indirect meta-Analysis. Haematologica 95:340-342.
171. Langer F, Dingemann J, Kreipe H, Lehmann U. (2005). Up-regulation of DNA methyltransferases DNMT1, 3A, and 3B in myelodysplastic syndrome. Leuk Res 29:325-329.
172. Lee JH, Choi Y, Kim SD, et al. (2013). Comparison of 7-day azacitidine and 5-day decitabine for treating myelodysplastic syndrome. Ann Hematol 92:889-897.
173. Leeke B, Marsman J, O'Sullivan JM, Horsfield JA. (2014). Cohesin mutations in myeloid malignancies: Underlying mechanisms. Exp Hematol Oncol 3:13. doi: 10.1186/2162-3619-3-13.
174. Levis M. (2013). Targeting IDH: The next big thing in AML. Blood 122: 2770-2771.
175. Ley TJ, Ding L, Walter MJ, et al. (2010). DNMT3A mutations in acute myeloid leukemia. N Engl J Med 363:2424-2433.
176. Li LH, Olin EJ, Buskirk HH, Reineke LM. (1970). Cytotoxicity and mode of action of 5-Azacytidine on L1210 leukemia. Cancer Res 30: 2760-2769.
177. Li Q, Liu L, Li W. (2014). Identification of circulating microRNAs as biomarkers in diagnosis of hematologic cancers: A meta-Analysis. Tumour Biol 35:10467-10478.
178. Li Z, Cai X, Cai CL, et al. (2011). Deletion of Tet2 in mice leads to dysregulated hematopoietic stem cells and subsequent development of myeloid malignancies. Blood 118:4509-4518.
179. Lin X, Wang Z, Zhang R, Feng W. (2014). High serum microRNA-335 level predicts aggressive tumor progression and unfavorable prognosis in pediatric acute myeloid leukemia. Clin Transl Oncol 2014 Oct 10. [Epub ahead of print].
180. Liu W, Deng L, Song Y, Redell M. (2014). DOT1L inhibition sensitizes MLL-rearranged AML to chemotherapy. PLoS One 9:e98270.
181. Liu X, Zhang G, Yi Y, et al. (2013). Decreased 5-hydroxymethylcytosine levels are associated with TET2 mutation and unfavorable overall survival in myelodysplastic syndromes. Leuk Lymphoma 54: 2466-2473.
182. Liu Z, Marcucci G, Byrd JC, et al. (2006). Characterization of decomposition products and preclinical and low dose clinical pharmacokinetics of decitabine (5-Aza-20-deoxycytidine) by a new liquid chromatography/tandem mass spectrometry quantification method. Rapid Commun Mass Spectrom 20:1117-1126.
183. Lopez-Serra L, Esteller M. (2008). Proteins that bind methylated DNA and human cancer: Reading the wrong words. Br J Cancer 98: 1881-1885.
184. Lorsbach RB, Moore J, Mathew S, et al. (2003). TET1, a member of a novel protein family, is fused to MLL in acute myeloid leukemia containing the t(10;11)(q22;q23). Leukemia 17:637-641.
185. Lorthongpanich C, Cheow LF, Balu S, et al. (2013). Single-cell DNAmethylation analysis reveals epigenetic chimerism in preimplantation embryos. Science 341:1110-1112.
186. Lu LJ, Randerath K. (1980). Mechanism of 5-Azacytidine-induced transfer RNA cytosine-5-methyltransferase deficiency. Cancer Res 40: 2701-2705.
187. Luger K, Mader AW, Richmond RK, et al. (1997). Crystal structure of the nucleosome core particle at 2.8 A resolution. Nature 389: 251-260.
188. Luo X, Liu Y, Kubicek S, et al. (2011). A selective inhibitor and probe of the cellular functions of Jumonji C domain-containing histone demethylases. J Am Chem Soc 133:9451-9456.
189. Madzo J, Vasanthakumar A, Godley LA. (2013). Perturbations of 5-hydroxymethylcytosine patterning in hematologic malignancies. Semin Hematol 50:61-69.
190. Maegawa S, Gough SM, Watanabe-Okochi N, et al. (2014). Age-related epigenetic drift in the pathogenesis of MDS and AML. Genome Res 24:580-591.
191. Mahfouz RZ, Jankowska A, Ebrahem Q, et al. (2013). Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-Azacytidine or decitabine therapy. Clin Cancer Res 19:938-948.
192. Malcovati L, Rumi E, Cazzola M. (2014). Somatic mutations of calreticulin in myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms. Haematologica 99:1650-1652.
193. Manodoro F, Marzec J, Chaplin T, et al. (2014). Loss of imprinting at the 14q32 domain is associated with microRNA overexpression in acute promyelocytic leukemia. Blood 123:2066-2074.
194. Marce S, Molina-Arcas M, Villamor N, et al. (2006). Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 91:895-902.
195. Marcucci G, Maharry K, Wu YZ, et al. (2010). IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 28:2348-2355.
196. Mardis ER, Ding L, Dooling DJ, et al. (2009). Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med 361:1058-1066.
197. Margueron R, Reinberg D. (2011). The polycomb complex PRC2 and its mark in life. Nature 469:343-349.
198. Marschalek R. (2011). Mechanisms of leukemogenesis by MLL fusion proteins. Br J Haematol 152:141-154.
199. Marsh JH, Kreis W, Barile B, et al. (1993). Therapy of refractory/relapsed acute myeloid leukemia and blast crisis of chronic myeloid leukemia with the combination of cytosine arabinoside, tetrahydrouridine, and carboplatin. Cancer Chemother Pharmacol 31:481-484.
200. Martin C, Zhang Y. (2005). The diverse functions of histone lysine methylation. Nat Rev Mol Cell Biol 6:838-849.
201. Matousova M, Votruba I, Otmar M, et al. (2011). 2-Deoxy-5, 6-dihydro-5-Azacytidine-A less toxic alternative of 2-deoxy-5-Azacytidine: A comparative study of hypomethylating potential. Epigenetics 6: 769-776.
202. Mayor R, Munoz M, Coolen MW, et al. (2011). Dynamics of bivalent chromatin domains upon drug induced reactivation and resilencing in cancer cells. Epigenetics 6:1138-1148.
203. McCabe MT, Brandes JC, Vertino PM. (2009). Cancer DNA methylation: Molecular mechanisms and clinical implications. Clin Cancer Res 15:3927-3937.
204. McCabe MT, Ott HM, Ganji G, et al. (2012). EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492:108-112.
205. Mercier C, Raynal C, Dahan L, et al. (2007). Toxic death case in a patient undergoing gemcitabine-based chemotherapy in relation with cytidine deaminase downregulation. Pharmacogenet Genomics 17: 841-844.
206. Merkerova MD, Krejcik Z, Belickova M, et al. (2014). Genome-wide miRNA profiling in myelodysplastic syndrome with del(5q) treated with lenalidomide. Eur J Haematol 2014 Oct 7. [Epub ahead of print]. doi: 10.1111/ejh.12458.
207. Mertz JA, Conery AR, Bryant BM, et al. (2011). Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108:16669-16674.
208. Metzeler KH, Becker H, Maharry K, et al. (2011). ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category. Blood 118:6920-6929.
209. Metzeler KH, Maharry K, Radmacher MD, et al. (2011). TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: A Cancer and Leukemia Group B study. J Clin Oncol 29:1373-1381.
210. Miremadi A, Oestergaard MZ, Pharoah PD, Caldas C. (2007). Cancer genetics of epigenetic genes. Hum Mol Genet 16 Spec No 1:R28-R49.
211. Mirza S, Sharma G, Parshad R, et al. (2013). Expression of DNA methyltransferases in breast cancer patients and to analyze the effect of natural compounds on DNA methyltransferases and associated proteins. J Breast Cancer 16:23-31.
212. Mochizuki N, Shimizu S, Nagasawa T, et al. (2000). A novel gene, MEL1, mapped to 1p36.3 is highly homologous to the MDS1/EVI1 gene and is transcriptionally activated in t(1;3)(p36;q21)-positive leukemia cells. Blood 96:3209-3214.
213. Mochly-Rosen D, Das K, Grimes KV. (2012). Protein kinase C, an elusive therapeutic target?. Nat Rev Drug Discov 11:937-957.
214. Molina-Arcas M, Bellosillo B, Casado FJ, et al. (2003). Fludarabine uptake mechanisms in B-cell chronic lymphocytic leukemia. Blood 101:2328-2334.
215. Momparler RL, Cote S, Momparler LF, Idaghdour Y. (2014). Epigenetic therapy of acute myeloid leukemia using 5-Aza-20-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation. Clin Epigenetics 6:19. doi: 10.1186/1868-7083-6-19.
216. Momparler RL, Derse D. (1979). Kinetics of phosphorylation of 5-Aza-20-deoxyycytidine by deoxycytidine kinase. Biochem Pharmacol 28: 1443-1444.
217. Momparler RL, Idaghdour Y, Marquez VE, Momparler LF. (2012). Synergistic antileukemic action of a combination of inhibitors of DNA methylation and histone methylation. Leuk Res 36:1049-1054.
218. Moran-Crusio K, Reavie L, Shih A, et al. (2011). Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. Cancer Cell 20:11-24.
219. Morin RD, Johnson NA, Severson TM, et al. (2010). Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat Genet 42:181-185.
220. Mossman D, Kim KT, Scott RJ. (2010). Demethylation by 5-Aza-20-deoxycytidine in colorectal cancer cells targets genomic DNA whilst promoter CpG island methylation persists. BMC Cancer 10:366.
221. Muller-Tidow C, Klein HU, Hascher A, et al. (2010). Profiling of histone H3 lysine 9 trimethylation levels predicts transcription factor activity and survival in acute myeloid leukemia. Blood 116: 3564-3571.
222. Murati A, Adelaide J, Mozziconacci MJ, et al. (2004). Variant MYST4-CBP gene fusion in a t(10;16) acute myeloid leukaemia. Br J Haematol 125:601-604.
223. Nakamura S, Tan L, Nagata Y, et al. (2013). JmjC-domain containing histone demethylase 1B-mediated p15(Ink4b) suppression promotes the proliferation of leukemic progenitor cells through modulation of cell cycle progression in acute myeloid leukemia. Mol Carcinog 52: 57-69.
224. Nakamura T, Largaespada DA, Lee MP, et al. (1996). Fusion of the nucleoporin gene NUP98 to HOXA9 by the chromosome translocation t(7;11)(p15;p15) in human myeloid leukaemia. Nat Genet 12: 154-158.
225. Nan X, Campoy FJ, Bird A. (1997). MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88:471-481.
226. Ng K, Pullirsch D, Leeb M, Wutz A. (2007). Xist and the order of silencing. EMBO Rep 8:34-39.
227. Nikoloski G, Langemeijer SM, Kuiper RP, et al. (2010). Somatic mutations of the histone methyltransferase gene EZH2 in myelodysplastic syndromes. Nat Genet 42:665-667.
228. Nikoloski G, van der Reijden BA, Jansen JH. (2012). Mutations in epigenetic regulators in myelodysplastic syndromes. Int J Hematol 95: 8-16.
229. Okada Y, Jiang Q, Lemieux M, et al. (2006). Leukaemic transformation by CALM-AF10 involves upregulation of Hoxa5 by hDOT1L. Nat Cell Biol 8:1017-1024.
230. Okano M, Bell DW, Haber DA, Li E. (1999). DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 99:247-257.
231. Olsnes AM, Ersvaer E, Ryningen A, et al. (2009). The protein kinase C agonist PEP005 increases NF-kappaB expression, induces differentiation and increases constitutive chemokine release by primary acute myeloid leukaemia cells. Br J Haematol 145:761-774.
232. Ooi SK, Qiu C, Bernstein E, et al. (2007). DNMT3L connects unmethylated lysine 4 of histone H3 to de novo methylation of DNA. Nature 448:714-717.
233. Oppikofer M, Kueng S, Gasser SM. (2013). SIR-nucleosome interactions: Structure-function relationships in yeast silent chromatin. Gene 527:10-25.
234. Otani J, Kimura H, Sharif J, et al. (2013). Cell cycle-dependent turnover of 5-hydroxymethyl cytosine in mouse embryonic stem cells. PLoS One 8:e82961.
235. Ozdag H, Teschendorff AE, Ahmed AA, et al. (2006). Differential expression of selected histone modifier genes in human solid cancers. BMC Genomics 7:90.
236. Panigrahi AK, Pati D. (2012). Higher-order orchestration of hematopoiesis: Is cohesin a new player?. Exp Hematol 40:967-973.
237. Parker PJ, Justilien V, Riou P, et al. (2014). Atypical protein kinase Ciota as a human oncogene and therapeutic target. Biochem Pharmacol 88: 1-11.
238. Parry L, Clarke AR. (2011). The roles of the methyl-CpG binding proteins in cancer. Genes Cancer 2:618-630.
239. Pastor WA, Pape UJ, Huang Y, et al. (2011). Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature 473: 394-397.
240. Patnaik MM, Hanson CA, Hodnefield JM, et al. (2012). Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic study of 277 patients. Leukemia 26: 101-105.
241. Patnaik MM, Itzykson R, Lasho TL, et al. (2014). ASXL1 and SETBP1 mutations and their prognostic contribution in chronic myelomonocytic leukemia: A two-center study of 466 patients. Leukemia 28: 2206-2212.
242. Patnaik MM, Padron E, LaBorde RR, et al. (2013). Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes. Leukemia 27: 1504-1510.
243. Pattabiraman DR, McGirr C, Shakhbazov K, et al. (2014). Interaction of c-Myb with p300 is required for the induction of acute myeloid leukemia (AML) by human AML oncogenes. Blood 123: 2682-2690.
244. Pearn L, Fisher J, Burnett AK, Darley RL. (2007). The role of PKC and PDK1 in monocyte lineage specification by Ras. Blood 109: 4461-4469.
245. Pennings S, Muyldermans S, Meersseman G, Wyns L. (1989). Formation, stability and core histone positioning of nucleosomes reassembled on bent and other nucleosome-derived DNA. J Mol Biol 207:183-192.
246. Perez-Duran P, de Yebenes V, Ramiro AR. (2007). Oncogenic events triggered by AID, the adverse effect of antibody diversification. Carcinogenesis 28:2427-2433.
247. Pfeifer GP, Xiong W, Hahn MA, Jin SG. (2014). The role of 5-hydroxymethylcytosine in human cancer. Cell Tissue Res 356: 631-641.
248. Phair RD, Scaffidi P, Elbi C, et al. (2004). Global nature of dynamic protein-chromatin interactions in vivo: Three-dimensional genome scanning and dynamic interaction networks of chromatin proteins. Mol Cell Biol 24:6393-6402.
249. Pleyer L, Burgstaller S, Girschikofsky M, et al. (2014). Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: Results from the Austrian Azacitidine Registry of the AGMT-Study Group. Ann Hematol 93:1825-1838.
250. Pleyer L, Germing U, Sperr WR, et al. (2014). Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival. Leuk Res 38:475-483.
251. Pleyer L, Stauder R, Burgstaller S, et al. (2013). Azacitidine in patients with WHO-defined AML-Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group. J Hematol Oncol 6:32. doi: 10.1186/1756-8722-6-32.
252. Pollyea DA, Raval A, Kusler B, et al. (2011). Impact of TET2 mutations on mRNA expression and clinical outcomes in MDS patients treated with DNA methyltransferase inhibitors. Hematol Oncol 29:157-160.
253. Poplineau M, Doliwa C, Schnekenburger M, et al. (2013). Epigenetically induced changes in nuclear textural patterns and gelatinase expression in human fibrosarcoma cells. Cell Prolif 46:127-136.
254. Puda A, Milosevic JD, Berg T, et al. (2012). Frequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies. Am J Hematol 87:245-250.
255. Qi W, Chan H, Teng L, et al. (2012). Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci USA 109:21360-21365.
256. Qin T, Castoro R, El Ahdab S, et al. (2011). Mechanisms of resistance to decitabine in the myelodysplastic syndrome. PLoS One 6:e23372.
257. Qin T, Jelinek J, Si J, et al. (2009). Mechanisms of resistance to 5-Aza-20-deoxycytidine in human cancer cell lines. Blood 113:659-667.
258. Qin W, Zhang K, Clarke K, et al. (2014). Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr Cancer 66:270-277.
259. Qu Y, Lennartsson A, Gaidzik VI, et al. (2014). Differential methylation in CN-AML preferentially targets non-CGI regions and is dictated by DNMT3A mutational status and associated with predominant hypomethylation of HOX genes. Epigenetics 9:1108-1119.
260. Quesnel B. (2009). Methyltransferases in myelodysplastic syndromes: Guilty or not guilty?. Leuk Res 33:601-602.
261. Quintas-Cardama A, Santos FP, Garcia-Manero G. (2011). Histone deacetylase inhibitors for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Leukemia 25:226-235.
262. Rathe SK, Largaespada DA. (2010). Deoxycytidine kinase is downregulated in Ara-C-resistant acute myeloid leukemia murine cell lines. Leukemia 24:1513-1515.
263. Raynal NJ, Si J, Taby RF, et al. (2012). DNA methylation does not stably lock gene expression but instead serves as a molecular mark for gene silencing memory. Cancer Res 72:1170-1181.
264. Raza A, Candoni A, Khan U, et al. (2004). Remicade as TNF suppressor in patients with myelodysplastic syndromes. Leuk Lymphoma 45: 2099-2104.
265. Raza A, Qawi H, Andric T, et al. (2000). Pentoxifylline, ciprofloxacin and dexamethasone improve the ineffective hematopoiesis in myelodysplastic syndrome patients; malignancy. Hematology 5: 275-284.
266. Raza A, Qawi H, Lisak L, et al. (2000). Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone. Blood 95: 1580-1587.
267. Redig AJ, Platanias LC. (2008). Protein kinase C signalling in leukemia. Leuk Lymphoma 49:1255-1262.
268. Reichman M, Penman S. (1973). The mechanism of inhibition of protein synthesis by 5-Azacytidine in HeLa cells. Biochim Biophys Acta 324: 282-289.
269. Reither S, Li F, Gowher H, Jeltsch A. (2003). Catalytic mechanism of DNA-(cytosine-C5)-methyltransferases revisited: Covalent intermediate formation is not essential for methyl group transfer by the murine Dnmt3a enzyme. J Mol Biol 329:675-684.
270. Ribeiro AF, Pratcorona M, Erpelinck-Verschueren C, et al. (2012). Mutant DNMT3A: A marker of poor prognosis in acute myeloid leukemia. Blood 119:5824-5831.
271. Rius M, Stresemann C, Keller D, et al. (2009). Human concentrative nucleoside transporter 1-mediated uptake of 5-Azacytidine enhances DNA demethylation. Mol Cancer Ther 8:225-231.
272. Romermann D, Hasemeier B, Metzig K, et al. (2008). Global increase in DNA methylation in patients with myelodysplastic syndrome. Leukemia 22:1954-1956.
273. Rosenthal A, Mesa RA. (2014). Janus kinase inhibitors for the treatment of myeloproliferative neoplasms. Expert Opin Pharmacother 15: 1265-1276.
274. Rottach A, Frauer C, Pichler G, et al. (2010). The multi-domain protein Np95 connects DNA methylation and histone modification. Nucleic Acids Res 38:1796-1804.
275. Saied MH, Marzec J, Khalid S, et al. (2012). Genome wide analysis of acute myeloid leukemia reveal leukemia specific methylome and subtype specific hypomethylation of repeats. PLoS One 7:e33213.
276. Saiki Y, Yoshino Y, Fujimura H, et al. (2012). DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells. Biochem Biophys Res Commun 421:98-104.
277. Santamaria C, Muntion S, Roson B, et al. (2012). Impaired expression of DICER, DROSHA, SBDS and some microRNAs in mesenchymal stromal cells from myelodysplastic syndrome patients. Haematologica 97:1218-1224.
278. Santi DV, Norment A, Garrett CE. (1984). Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-Azacytosine. Proc Natl Acad Sci USA 81:6993-6997.
279. Santini V, Melnick A, Maciejewski JP, et al. (2013). Epigenetics in focus: Pathogenesis of myelodysplastic syndromes and the role of hypomethylating agents. Crit Rev Oncol Hematol 88:231-245.
280. Santini V. (2009). Azacitidine: Activity and efficacy as an epigenetic treatment of myelodysplastic syndromes. Expert Rev Hematol 2: 121-127.
281. Sashida G, Harada H, Matsui H, et al. (2014). Ezh2 loss promotes development of myelodysplastic syndrome but attenuates its predisposition to leukaemic transformation. Nat Commun 5:4177. doi:10.1038/ncomms5177.
282. Score J, Hidalgo-Curtis C, Jones AV, et al. (2012). Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasms. Blood 119: 1208-1213.
283. Scott BL, Ramakrishnan A, Fosdal M, et al. (2010). Anti-Thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): A phase II study. Br J Haematol 149:706-710.
284. Scott BL, Ramakrishnan A, Storer B, et al. (2010). Prolonged responses in patients with MDS and CMML treated with azacitidine and etanercept. Br J Haematol 148:944-947.
285. Shah N, Sukumar S. (2010). The Hox genes and their roles in oncogenesis. Nat Rev Cancer 10:361-371.
286. Sharif J, Muto M, Takebayashi S, et al. (2007). The SRA protein Np95 mediates epigenetic inheritance by recruiting Dnmt1 to methylated DNA. Nature 450:908-912.
287. Shen L, Kantarjian H, Guo Y, et al. (2010). DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 28:605-613.
288. Shigeno K, Yoshida H, Pan L, et al. (2004). Disease-related potential of mutations in transcriptional cofactors CREB-binding protein and p300 in leukemias. Cancer Lett 213:11-20.
289. Shih AH, Abdel-Wahab O, Patel JP, Levine RL. (2012). The role of mutations in epigenetic regulators in myeloid malignancies. Nat Rev Cancer 12:599-612.
290. Sokol L, Caceres G, Volinia S, et al. (2011). Identification of a risk dependent microRNA expression signature in myelodysplastic syndromes. Br J Haematol 153:24-32.
291. Song CX, Szulwach KE, Fu Y, et al. (2011). Selective chemical labeling reveals the genome-wide distribution of 5-hydroxymethylcytosine. Nat Biotechnol 29:68-72.
292. Sorm F, Piskala A, Cihak A, Vesely J. (1964). 5-Azacytidine, a new, highly effective cancerostatic. Experientia 20:202-203.
293. Spada F, Haemmer A, Kuch D, et al. (2007). DNMT1 but not its interaction with the replication machinery is required for maintenance of DNA methylation in human cells. J Cell Biol 176: 565-571.
294. Sroczynska P, Cruickshank VA, Bukowski JP, et al. (2014). shRNA screening identifies JMJD1C as being required for leukemia maintenance. Blood 123:1870-1882.
295. Stasi R, Amadori S, Newland AC, Provan D. (2005). Infliximab chimeric antitumor necrosis factor-A monoclonal antibody as potential treatment for myelodysplastic syndromes. Leuk Lymphoma 46:509-516.
296. Steinberg SF. (2004). Distinctive activation mechanisms and functions for protein kinase Cdelta. Biochem J 384:449-459.
297. Stewart HJ, Horne GA, Bastow S, Chevassut TJ. (2013). BRD4 associates with p53 in DNMT3A-mutated leukemia cells and is implicated in apoptosis by the bromodomain inhibitor JQ1. Cancer Med 2:826-835.
298. Stintzing S, Kemmerling R, Kiesslich T, et al. (2011). Myelodysplastic syndrome and histone deacetylase inhibitors: to be or not to be acetylated?. J Biomed Biotechnol 2011:214143. doi: 10.1155/2011/214143.
299. Stresemann C, Lyko F. (2008). Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine. Int J Cancer 123:8-13.
300. Su R, Lin HS, Zhang XH, et al. (2014). MiR-181 family: Regulators of myeloid differentiation and acute myeloid leukemia as well as potential therapeutic targets. Oncogene 2014 Sep 1. [Epub ahead of print]. doi: 10.1038/onc.2014.274.
301. Suzuki M, Yamada T, Kihara-Negishi F, et al. (2003). Direct association between PU.1 and MeCP2 that recruits mSin3A-HDAC complex for PU.1-mediated transcriptional repression. Oncogene 22: 8688-8698.
302. Suzuki M, Yamada T, Kihara-Negishi F, et al. (2006). Site-specific DNA methylation by a complex of PU.1 and Dnmt3a/b. Oncogene 25: 2477-2488.
303. Tahiliani M, Koh KP, Shen Y, et al. (2009). Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 324:930-935.
304. Takai A, Marusawa H, Minaki Y, et al. (2012). Targeting activationinduced cytidine deaminase prevents colon cancer development despite persistent colonic inflammation. Oncogene 31: 1733-1742.
305. Talbert PB, Henikoff S. (2006). Spreading of silent chromatin: Inaction at a distance. Nat Rev Genet 7:793-803.
306. Tanaka S, Miyagi S, Sashida G, et al. (2012). Ezh2 augments leukemogenicity by reinforcing differentiation blockage in acute myeloid leukemia. Blood 120:1107-1117.
307. Tark-Dame M, Jerabek H, Manders EM, et al. (2014). Depletion of the chromatin looping proteins CTCF and cohesin causes chromatin compaction: Insight into chromatin folding by polymer modelling. PLoS Comput Biol 10:e1003877.
308. Tenen DG, Hromas R, Licht JD, Zhang DE. (1997). Transcription factors, normal myeloid development, and leukemia. Blood 90: 489-519.
309. Thol F, Bollin R, Gehlhaar M, et al. (2014). Mutations in the cohesin complex in acute myeloid leukemia: Clinical and prognostic implications. Blood 123:914-920.
310. Thol F, Damm F, Ludeking A, et al. (2011). Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 29:2889-2896.
311. Thol F, Friesen I, Damm F, et al. (2011). Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes. J Clin Oncol 29:2499-2506.
312. Tien HF, Tang JH, TsayW, et al. (2001). Methylation of the p15(INK4B) gene in myelodysplastic syndrome: It can be detected early at diagnosis or during disease progression and is highly associated with leukaemic transformation. Br J Haematol 112:148-154.
313. Timp W, Feinberg AP. (2013). Cancer as a dysregulated epigenome allowing cellular growth advantage at the expense of the host. Nat Rev Cancer 13:497-510.
314. Torrano V, Chernukhin I, Docquier F, et al. (2005). CTCF regulates growth and erythroid differentiation of human myeloid leukemia cells. J Biol Chem 280:28152-28161.
315. Toyota M, Ahuja N, Ohe-Toyota M, et al. (1999). CpG island methylator phenotype in colorectal cancer. Proc Natl Acad Sci USA 96: 8681-8686.
316. Traina F, Visconte V, Elson P, et al. (2014). Impact of molecular mutations on treatment response to DNMT inhibitors in myelodysplasia and related neoplasms. Leukemia 28:78-87.
317. Trubia M, Albano F, Cavazzini F, et al. (2006). Characterization of a recurrent translocation t(2;3)(p15-22;q26) occurring in acute myeloid leukaemia. Leukemia 20:48-54.
318. Tsai CT, Yang PM, Chern TR, et al. (2014). AID downregulation is a novel function of the DNMT inhibitor 5-Aza-deoxycytidine. Oncotarget 5:211-223.
319. Ufkin ML, Peterson S, Yang X, et al. (2014). miR-125a regulates cell cycle, proliferation, and apoptosis by targeting the ErbB pathway in acute myeloid leukemia. Leuk Res 38:402-410.
320. Unoki M, Brunet J, Mousli M. (2009). Drug discovery targeting epigenetic codes: The great potential of UHRF1, which links DNA methylation and histone modifications, as a drug target in cancers and toxoplasmosis. Biochem Pharmacol 78:1279-1288.
321. Valencia A, Masala E, Rossi A, et al. (2014). Expression of nucleosidemetabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine. Leukemia 28:621-628.
322. Valent P, Zuber J. (2014). BRD4: A BET(ter) target for the treatment of AML?. Cell Cycle 13:689-690.
323. Valinluck V, Tsai HH, Rogstad DK, et al. (2004). Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2 Nucleic Acids Res 32:4100-4108.
324. van Groeningen CJ, Leyva A, O'Brien AM, et al. (1986). Phase I and pharmacokinetic study of 5-Aza-20-deoxycytidine (NSC 127716) in cancer patients. Cancer Res 46:4831-4836.
325. Van Rompay AR, Norda A, Linden K, et al. (2001). Phosphorylation of uridine and cytidine nucleoside analogs by two human uridinecytidine kinases. Mol Pharmacol 59:1181-1186.
326. Varambally S, Cao Q, Mani RS, et al. (2008). Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science 322:1695-1699.
327. Vasilatou D, Papageorgiou S, Pappa V, et al. (2010). The role of microRNAs in normal and malignant hematopoiesis. Eur J Haematol 84:1-16.
328. Vasilatou D, Papageorgiou SG, Dimitriadis G, Pappa V. (2013). Epigenetic alterations and microRNAs: New players in the pathogenesis of myelodysplastic syndromes. Epigenetics 8:561-570.
329. Veuger MJ, Honders MW, Spoelder HE, et al. (2003). Inactivation of deoxycytidine kinase and overexpression of P-glycoprotein in AraC and daunorubicin double resistant leukemic cell lines. Leuk Res 27: 445-453.
330. Voso MT, Fabiani E, Piciocchi A, et al. (2011). Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine. Leukemia 25:1910-1913.
331. Voso MT, Santini V, Fabiani E, et al. (2014). Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica 99:613-619.
332. Walter MJ, Ding L, Shen D, et al. (2011). Recurrent DNMT3A mutations in patients with myelodysplastic syndromes. Leukemia 25: 1153-1158.
333. Wang J, Ai X, Gale RP, et al. (2013). TET2, ASXL1 and EZH2 mutations in Chinese with myelodysplastic syndromes. Leuk Res 37: 305-311.
334. Wang J, Li Z, He Y, et al. (2014). Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice. Blood 123:541-553.
335. Wang X, Dai H, Wang Q, et al. (2013). EZH2 mutations are related to low blast percentage in bone marrow and-7/del(7q) in de novo acute myeloid leukemia. PLoS One 8:e61341.
336. Ward PS, Patel J, Wise DR, et al. (2010). The common feature of leukemia-Associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate. Cancer Cell 17:225-234.
337. Wodarz D, Boland CR, Goel A, Komarova NL. (2013). Methylation kinetics and CpG-island methylator phenotype status in colorectal cancer cell lines. Biol Direct 8:14. doi: 10.1186/1745-6150-8-14.
338. Wong YF, Jakt LM, Nishikawa S. (2013). Prolonged treatment with DNMT inhibitors induces distinct effects in promoters and genebodies. PLoS One 8:e71099.
339. Xiao M, Yang H, Xu W, et al. (2012). Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev 26:1326-1338.
340. Xu F, Li X, Wu L, et al. (2011). Overexpression of the EZH2, RING1 and BMI1 genes is common in myelodysplastic syndromes: Relation to adverse epigenetic alteration and poor prognostic scoring. Ann Hematol 90:643-653.
341. Xu F, Li X. (2012). The role of histone methyltransferase EZH2 in myelodysplastic syndromes. Expert Rev Hematol 5:177-185.
342. Xu M, Zhao GN, Lv X, et al. (2014). CTCF controls HOXA cluster silencing and mediates PRC2-repressive higher-order chromatin structure in NT2/D1 cells. Mol Cell Biol 34:3867-3879.
343. Xu W, Podoll JD, Dong X, et al. (2013). Quantitative analysis of histone demethylase probes using fluorescence polarization. J Med Chem 56: 5198-5202.
344. Yamazaki J, Estecio MR, Lu Y, et al. (2013). The epigenome of AML stem and progenitor cells. Epigenetics 8:92-104.
345. Yamazaki J, Taby R, Vasanthakumar A, et al. (2012). Effects of TET2 mutations on DNA methylation in chronic myelomonocytic leukemia. Epigenetics 7:201-207.
346. Yan J, Enge M, Whitington T, et al. (2013). Transcription factor binding in human cells occurs in dense clusters formed around cohesin anchor sites. Cell 154:801-813.
347. Yan P, Frankhouser D, Murphy M, et al. (2012). Genome-wide methylation profiling in decitabine-Treated patients with acute myeloid leukemia. Blood 120:2466-2474.
348. Yan XJ, Xu J, Gu ZH, et al. (2011). Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 43:309-315.
349. Yang AS, Doshi KD, Choi SW, et al. (2006). DNA methylation changes after 5-Aza-20-deoxycytidine therapy in patients with leukemia. Cancer Res 66:5495-5503.
350. Yang X, Noushmehr H, Han H, et al. (2012). Gene reactivation by 5-Aza-20-deoxycytidine-induced demethylation requires SRCAP-mediated H2A.Z insertion to establish nucleosome depleted regions. PLoS Genet 8:e1002604.
351. Yang XJ. (2004). The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases. Nucleic Acids Res 32: 959-976.
352. Yildirim O, Li R, Hung JH, et al. (2011). Mbd3/NURD complex regulates expression of 5-hydroxymethylcytosine marked genes in embryonic stem cells. Cell 147:1498-1510.
353. Yin B, Tsai ML, Hasz DE, et al. (2007). A microarray study of altered gene expression after cytarabine resistance in acute myeloid leukemia. Leukemia 21:1093-1097.
354. Yoo CB, Jeong S, Egger G, et al. (2007). Delivery of 5-Aza-20-deoxycytidine to cells using oligodeoxynucleotides. Cancer Res 67: 6400-6408.
355. Zardo G, Ciolfi A, Vian L, et al. (2012). Polycombs and microRNA-223 regulate human granulopoiesis by transcriptional control of target gene expression. Blood 119:4034-4046.
356. Zhao M, Rudek MA, He P, et al. (2004). Quantification of 5-Azacytidine in plasma by electrospray tandem mass spectrometry coupled with high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 813:81-88.
357. Zhao Q, Fan J, Hong W, et al. (2012). Inhibition of cancer cell proliferation by 5-fluoro-20-deoxycytidine, a DNA methylation inhibitor, through activation of DNA damage response pathway. Springerplus 1:65. doi: 10.1186/2193-1801-1-65.
358. Zhao X, Yang F, Li S, et al. (2014). CpG island methylator phenotype of myelodysplastic syndrome identified through genome-wide profiling of DNA methylation and gene expression. Br J Haematol 165: 649-658.
359. Zhou J, Bi C, Cheong LL, et al. (2011). The histone methyltransferase inhibitor, DZNep, up-regulates TXNIP, increases ROS production, and targets leukemia cells in AML. Blood 118:2830-2839.
360. Zhu WG, Otterson GA. (2003). The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells. Curr Med Chem Anticancer Agents 3:187-199.
361. Zhu ZZ, Hou L, Bollati V, et al. (2012). Predictors of global methylation levels in blood DNA of healthy subjects: A combined analysis. Int J Epidemiol 41:126-139.
362. Zuber J, Shi J, Wang E, et al. (2011). RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478: 524-528.